arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Corvus Pharmaceuticals, Inc.

CRVS

$9.73 ▼ -0.86 (-8.07%) at close

12 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Corvus Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $768.3M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -55.5% ↗

FCF / Share $-0.42 →

Trailing P/E —

Price / Book 11.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-15.28M

↑ +75.5% —

FCF / Share Free cash flow per share

$-0.42

— -0.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
EPS Growth YoY (%)	81.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-82.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	37.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	13.6% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-415.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	75.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-130.5% Weak ↑ Weak Improving Year-over-year change in net income	34.6% Excellent ↑ Excellent Improving Year-over-year change in net income	4.5% Caution ↑ Caution Improving Year-over-year change in net income	-621.3% Weak ↓ Weak Declining Year-over-year change in net income	87.2% Excellent ↑ Excellent Improving Year-over-year change in net income	0.6% Caution ↑ Caution Improving Year-over-year change in net income	15.7% Good ↑ Good Improving Year-over-year change in net income	-53.0% Weak ↑ Weak Improving Year-over-year change in net income	-16.1% Weak Weak Year-over-year change in net income	-19362.7% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	-0.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	16.5% Good ↓ Good Declining Year-over-year change in free cash flow	14.9% Fair ↓ Fair Declining Year-over-year change in free cash flow	33.2% Excellent Excellent Year-over-year change in free cash flow	25.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	2.16x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	5.81x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-55.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-66.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-58.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-39.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-60.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-68.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	44.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	80.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-60.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-35.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-58.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-14.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-25.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-266%)	-191.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1375%)	-69.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-566%)	-73.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-591%)	-44.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-397%)	-8.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-155%)	-65.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-538%)	-42.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-384%)	-65.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-537%)	-27.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-283%)	100.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+572%)	101.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+575%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Net Debt (USD)	$-4.58M	$-8.74M	$-12.62M	$-13.16M	$-63.46M	$-16.45M	$-5.15M	$-39.20M	$-45.11M	$-5.05M	$-4.11M	$-12.52M

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Basic EPS, GAAP (USD)	$-0.19	$-1.02	$-0.56	$-0.89	$-1.03	$-0.20	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.42	$-0.42	$-0.50	$-0.59	$-0.88	$-1.18	—	—	—	—	—	—
Book Value per Share (USD)	$0.82	$0.48	$0.79	$1.21	$2.32	$2.54	$2.54	$3.76	$4.03	$6.35	$-21.72	—
Tangible Book Value per Share (USD)	$0.82	$0.48	$0.79	$1.21	$2.32	$2.54	$2.54	$3.76	$4.03	$6.35	$-21.72	—
Basic Weighted Avg Shares (shares)	78.96M	60.99M	48.03M	46.55M	41.85M	29.48M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$48.83M	$19.00M	$21.09M	$32.91M	$61.62M	$33.19M	$69.12M	$108.56M	$82.27M	$130.09M	$92.59M	—
Total Equity (USD)	$61.20M	$32.57M	$38.68M	$56.12M	$97.16M	$72.15M	$71.11M	$110.34M	$84.83M	$132.80M	$-31.10M	$-159.00K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Depreciation Expense (USD)	$105.00K	$85.00K	$151.00K	$367.00K	$460.00K	$632.00K	$743.00K	$847.00K	$842.00K	$594.00K	$148.00K	—
Net Income, GAAP (USD)	$-15.28M	$-62.29M	$-27.03M	$-41.31M	$-43.24M	$-6.00M	$-46.67M	$-46.94M	$-55.66M	$-36.38M	$-31.34M	$-161.00K
Operating Cash Flow (USD)	$-32.80M	$-25.42M	$-23.93M	$-27.02M	$-36.72M	$-34.78M	$-37.32M	$-40.99M	$-46.21M	$-27.86M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 47 quarters

Corvus Pharmaceuticals, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CRVS with peers